Iovance Biotherapeutics

IOVA64

High Growth

$9.69arrow_drop_down8.92%-$0.95

High Growth

IOVA64

$9.69

arrow_drop_down8.92%-$0.95

High Growth

Performance History

Key Stats
Open	$10.48
Prev. Close	$10.58
EPS	-1.48
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	10.06	10.84
52 Week Range	3.21	18.33

Ratios







EPS	-1.48

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics Inc (IOVA) is a biopharmaceutical company that focuses on developing and commercializing cell-based cancer immunotherapies. The company's lead product candidate is LN-144, an adoptive cell therapy that is being developed for the treatment of patients with metastatic melanoma. LN-144 utilizes Tumor-Infiltrating Lymphocytes (TILs), which are extracted from a patient's tumor and then expanded in the laboratory. The expanded TILs are then infused back into the patient with the goal of targeting and killing the cancer cells.

Iovance Biotherapeutics Inc aims to revolutionize cancer treatment by harnessing the power of the immune system. The company believes that by leveraging the body's own immune cells, they can develop targeted therapies that are more effective and less toxic than traditional cancer treatments. The potential of their cell-based immunotherapies has been demonstrated in early clinical trials, with promising results in melanoma and other solid tumors.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Headquarters: San Carlos
Employees: 503
Exchange: NASDAQ

add Iovance Biotherapeutics to watchlist

Keep an eye on Iovance Biotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Iovance Biotherapeutics 's (IOVA) price per share?

The current price per share for Iovance Biotherapeutics (IOVA) is $9.69. The stock has seen a price change of -$0.95 recently, indicating a -8.92% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Iovance Biotherapeutics (IOVA)?

For Iovance Biotherapeutics (IOVA), the 52-week high is $18.33, which is 89.16% from the current price. The 52-week low is $3.21, the current price is 201.87% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Iovance Biotherapeutics (IOVA) a growth stock?

Iovance Biotherapeutics (IOVA) has shown an average price growth of -3.67% over the past three years. It has received a score of 72 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Iovance Biotherapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Iovance Biotherapeutics (IOVA) stock price performance year to date (YTD)?

As of the latest data, Iovance Biotherapeutics (IOVA) has a year-to-date price change of 19.63%. Over the past month, the stock has experienced a price change of -0.51%. Over the last three months, the change has been -3.92%. Over the past six months, the figure is -10.94%. Looking at a longer horizon, the five-year price change stands at -59.41%.

help

Is Iovance Biotherapeutics (IOVA) a profitable company?

Iovance Biotherapeutics (IOVA) has a net income of -$444.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -152.11% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.19M, although specific revenue growth data is currently not available. Operating income is noted at -$460.56M. Furthermore, the EBITDA is -$408.32M.

help

What is the market capitalization of Iovance Biotherapeutics (IOVA)?

Iovance Biotherapeutics (IOVA) has a market capitalization of $3.05B. The average daily trading volume is 9.94, indicating the stock's liquidity and investor engagement.